SurfWax News Index  |  Track News  |  Save/Exchange Information |  About Us

    News and Articles on Head and Neck Cancer

    Archives: Head and Neck Cancer

    YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER  Jan 6, 2009
    Unrelated to the rash, Grade III/IV radiation dermatitis is a severe toxicity reported in almost half the patients treated with another EGFR-targeting antibody drug in combination with radiation in head and neck cancer while absent in nimotuzumab/radiation treated patients. Reports of any severe incidents of the other side-effects that are typical of EGFR-targeting molecules have been rare. (PR Newswire)

    Small Molecules, Large Effect: How Cancer Cells Ensure Their Survival  Jan 1, 2009
    Fetz, V., Bier, C., Habtemichael, N., Schuon, R., Schweitzer, A., Kunkel, M., Engels, K., Kovacs, A. F., Schneider, S., Mann, W., Stauber, R. H., and Knauer, S. K. Survivin-mediated chemoresistance is modulated by iNOS in head and neck cancer cells. International Journal of Cancer, DOI. (Science Daily)

    MRSA pre-screening effective in reducing otolaryngic surgical infection rates  Jan 1, 2009
    Due to particular concerns about MRSA infections in otolaryngic surgeries, the authors recommend further, larger studies, with an emphasis on high-risk patients, including those with multiple comorbidities, head and neck cancer patients, patients receiving implanted devices, and patients with prior hospitalizations or multiple courses of antibiotics. . (EurekAlert!)

    Women Double Fruit, Veggie Intake With Switch To Mediterranean Diet Plan  Dec 31, 2008
    16, 2007) A new study among AARP members shows that just one additional serving of fruit and vegetables per day may lower your risk of head and neck cancer, but the data suggest that you may not want to stop. (July 18, 2007) Eating double the amount of veggies and fruits recommended by general dietary guidelines doesn't reduce the likelihood of breast cancer recurrence among women whose cancers were treated at an early. (Science Daily)

    Cancer Treatments Redefined To Reduce Potential Nerve Damage  Dec 21, 2008
    20, 2008) While radiation treatments deliver precise doses of high-energy X-rays to stop cancer cells from spreading or to shrink tumors, oncologists have become increasingly concerned about inadvertent exposures during head and neck cancer treatments to nerves responsible for upper body mobility ... "Radiation is an essential treatment for most head and neck cancers, and current technologies make it possible for us to successfully target those tumors," said Chen ... He then designed delivery... (Science Daily)

    Cetuximab in Head and Neck Cancer  Dec 18, 2008
    To the Editor: The study of chemotherapy plus cetuximab in patients with head and neck cancer, reported by Vermorken et al. (Sept. 11 issue),1 is limited by the fact that enrollment was restricted to patients with a good Karnofsky performance score (70 or more). (New England Journal of Medicine)

    Oral Cancer Patients Could Be Diagnosed Earlier, Study Suggests  Dec 13, 2008
    The majority of oral, head and neck cancer are initially diagnosed in a late stage, which has a five year prognosis of less than 50 percent ... 9, 2008) The human papillomavirus allows infected cervical and head and neck cancer cells to maintain internal molecular conditions that make the cancers resistant to therapy and more likely to grow and. (Science Daily)

    Introgen files Chapter 11  Dec 5, 2008
    Introgen s major troubles began in July when analysts began questioning the effectiveness of its much-touted head and neck cancer drug Advexin. That set the company s stock in a downward spiral from which it still not recovered. (Austin Business Journal, TX)

    The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types  Dec 5, 2008
    Nasopharyngeal carcinoma (NPC) and other head and neck cancer (HNCA) types show a great epidemiological variation in different regions of the world. NPC has multifactorial etiology and many interacting risk factors are involved in NPC development mainly Epstein Barr virus (EBV). (BioMed Central)

    Introgen files for Chapter 11  Dec 4, 2008
    Introgen s major troubles began in July when analysts began questioning the effectiveness of its much-touted head and neck cancer drug, Advexin. That set the company s stock in a downward spiral from which it still has not recovered. (Houston Business Journal, TX)

    Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer  Dec 4, 2008
    3, 2008) Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests. In laboratory tests, hormones produced by fat cells stimulate breast cancer cells to migrate and invade surrounding tissues, scientists at Emory University School of Medicine found. (Science Daily)

    Merck working with cancer center on study  Dec 3, 2008
    That list includes nonsmall cell lung cancer, head and neck cancer, pancreatic adenocarcinoma, and brain metastases from a solid tumor with an emphasis on lung cancer. Vorinostat is the active ingredient in Zolinza, a Merck (NYSE:MRK) drug approved for patients with progressive, persistent or recurrent cutaneous T-cell lymphoma. (Philadelphia Business Journal, PA)

    Acupuncture beats aspirin for chronic headache  Dec 3, 2008
    Other studies have shown that acupuncture helped alleviate pain in patients who had surgery for head and neck cancer, can relieve hot flashes and other menopausal symptoms and can reduce chemotherapy-induced nausea. Copyright 2008 Reuters. (MSNBC -- Health)

    Three Esophageal, Stomach Cancer Subtypes Linked To Smoking; One Associated With Alcohol Use  Dec 1, 2008
    "Smoking is a risk factor for both cancers, but since a decreasing part of the population smokes, this cannot explain why the incidence is rising so rapidly for both cancers in Western countries in recent decades. "Other factors that might be associated with the risk of these cancers include obesity, diet and nutrition, exercise, occupational exposures, medical factors and so forth, which we are beginning to study," Steevens said. Their findings are from one of the first large cohort studies to... (Science Daily)

    Fort Washington-based cancer group funded  Nov 25, 2008
    Cetuximab is the active ingredient in Erbitux, marketed by Bristol-Myers Squibb (NYSE:BMY) and ImClone as a treatment for metastatic colorectal cancer and advanced head and neck cancer. The National Comprehensive Cancer Network, a nonprofit based in Fort Washington, Pa. (Philadelphia Business Journal, PA)

    No cover-up in cancer treatment errors  Nov 25, 2008
    It also revealed a head and neck cancer patient had their care compromised by two per cent and required future monitoring. The review ordered future monitoring for a prostate cancer patient who received radiotherapy as the only treatment for the condition. (The Age)

    New Platinum-phosphate Compounds Kill Ovarian Cancer Cells, Other Cancer Cells  Nov 21, 2008
    20, 2008) A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published in the journal Proceedings of the National Academy of Sciences. See also. (Science Daily)

    Introgen moved from Nasdaq Global Market  Nov 20, 2008
    In early September, Introgen was dealt a significant blow when the U.S. Food and Drug Administration declined to accept the company s application to market its head and neck cancer drug Advexin. Introgen has spent more than a decade developing Advexin. (Austin Business Journal, TX)

    Survival of head and neck cancer patients is greatly affected by coexisting ailments  Nov 20, 2008
    Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital ... In a recent study, Piccirillo, director of the Clinical Outcomes Research Office at Washington University School of Medicine and... (EurekAlert!)

    Smoking, Drinking Raise Risks of Esophagus, Stomach Cancer  Nov 19, 2008
    The study focused on: esophageal squamous cell carcinoma (ESCC), which resembles head and neck cancer; esophageal adenocarcinoma (EAC), typically found in the lower esophagus; and gastric cardia adenocarcinoma (GCA), a cancer that occurs in the area of the upper stomach where it joins the esophagus. After 16 years, there had been 120 ESCC cases, 168 EAC cases and 187 GCA cases among the study participants. (MEDLINEplus)

    Kids Not Eating Their Five Fruits Or Vegetables A Day, UK Study Shows  Nov 19, 2008
    16, 2007) A new study among AARP members shows that just one additional serving of fruit and vegetables per day may lower your risk of head and neck cancer, but the data suggest that you may not want to stop. . (Science Daily)

    'Two-headed' Antibody Poses A Double Threat To Breast Cancer Cells, Say Researchers  Nov 15, 2008
    ALM's targets are two signaling proteins, ErbB2 and ErbB3, which connect to form a growth-promoting complex on the surface of many cancer cells, including head and neck cancer and drug-resistant breast cancer. "ALM grabs the ErbB2-ErbB3 complex strongly with both hands, as it were, providing a solid grip on the tumor and blocking the transmission of a growth signal within the cell," said lead investigator Matthew Robinson, PhD, an associate member of Fox Chase and a researcher in the Fox Chase... (Science Daily)

    HPV Virus Helps Cervical And Head And Neck Cancers Resist Treatment And Grow And Spread  Nov 10, 2008
    9, 2008) The human papillomavirus (HPV) allows infected cervical and head and neck cancer cells to maintain internal molecular conditions that make the cancers resistant to therapy and more likely to grow and spread, resulting in a poor prognosis for patients, researchers with UCLA's Jonsson Cancer Center found ... About 400,000 cases of head and neck cancer are diagnosed worldwide each year, and more than half of those patients die of the disease ... Cervical and head and neck cancers not... (Science Daily)

    Special Mouth Rinse Spots, Tracks Human Papillomavirus Infection  Nov 4, 2008
    The researchers followed 135 patients with head and neck cancer over five years, and found that the patients with HPV-16 positive tumors were far more likely to test positive for oral HPV-16 infections before, during, and after therapy. Although past research has shown a strong association between cancers of the head and neck and HPV-16 infection, these researchers used genetic sequencing to confirm the link between HPV-16 infection and HPV-16 shed by tumors in patients with head and neck... (MEDLINEplus)

    Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test  Nov 4, 2008
    Head and neck cancer is the broad term for a variety of cancers of the oral cavity, including the tonsils, base of the tongue, and the side and back wall of the throat. The study found that oral rinses successfully detected high-risk HPV infections in patients with HPV 16-positive head and neck cancers for up to five years after treatment for their cancer ... Gillison says the findings indicate a high rate of persistent infection and reaffirms the connection between high-risk types of HPV and... (EurekAlert!)

    Oral rinses used for tracking HPV-positive head and neck cancers holds promise for cancer screening  Oct 31, 2008
    PHILADELPHIA A study published in the journal Clinical Cancer Research, a journal of the American Association for Cancer Research, validates a non-invasive screening method with future potential for detection of human papillomavirus (HPV)-positive head and neck cancers ... Findings showed detection of high-risk HPV infections in patients with HPV16-positive HNSCC for up to five years after therapy, indicating a high rate of persistent infection and reaffirming the connection between high-risk... (EurekAlert!)

    Chest CT Scans Detect Spread of Head, Neck Cancers  Oct 23, 2008
    TUESDAY, Oct. 21 (HealthDay News) -- CT scans of the chest may help detect disease progression in high-risk patients with head and neck cancer, say researchers in Taiwan. They evaluated 270 screening chest CT scans conducted over 42 months in 192 patients with head and neck squamous cell carcinoma, which accounts for most head and neck cancers. (MEDLINEplus)

    Chest Scans May Help Monitor Spread Of Head And Neck Cancer In High-risk Patients  Oct 23, 2008
    23, 2008) Among high-risk patients with head and neck cancer, chest computed tomography (CT) may help detect disease progression involving the lungs, according to a new report ... Developing a second, distant cancer (a metastasis or a new primary cancer) is an important factor affecting survival of patients with head and neck squamous cell carcinoma, which accounts for most head and neck cancers, according to background information in the article ... Yen-Bin Hsu, MD; Pen-Yuan Chu, MD;... (Science Daily)

    Foreign docs bring home message on cancer  Oct 21, 2008
    MUMBAI: A group of seven leading specialists who have been globe-trotting with a special message -- to spread the word on preventing head and neck cancer -- stopped by in Mumbai on Monday ... "If we can prevent people from tobacco use, it will be a bigger advance in the field of head and neck cancer than molecular biology,'' said Dr Jatin Shah of the International Federation of Head and Neck Oncologic Societies (IFHNOS) who is spearheading the world tour. The doctors who have taken five weeks... (Times of India)

    Nicotine May Spur Breast Cancer's Spread  Oct 18, 2008
    Nicotine, a component of tobacco, has been connected with a variety of malignancies -- not only lung cancer, but also head and neck cancer, prostate cancer, and more. "It has been known that there are 10 to 12 nicotine receptors that express on the surface of various cells," Chen explained. (MEDLINEplus)

    Local Study Seeks To Ease Cancer Patients' Depression  Oct 18, 2008
    -- Nebraska researchers are looking at ways to cut down on depression that can occur in patients diagnosed with head and neck cancer. Patients that came through our clinics with head and neck cancer frequently developed major depression, said oncologist Dr. William Lydiatt ... Lydiatt led a study focused on a small group of head and neck cancer patients, giving some of them an anti-depressant. (7 KETV Omaha)

    Breast cancer awareness month spotlights oral mucositis: Side effect of anticancer therapy  Oct 17, 2008
    OM affects approximately 40 percent of cancer patients who receive chemotherapy, more than 70 percent of those undergoing conditioning therapy for bone marrow transplantation, and virtually all patients receiving radiation therapy for head and neck cancer. "Given the large numbers of women receiving chemotherapy for breast cancer, oral mucositis is something that every patient, caregiver and family member should be aware of," commented Anne Marie Shaftic, MSN, RN, Oncology Nurse Practitioner in... (EurekAlert!)

    Racial Disparities Exist in Head and Neck Cancer Outcomes  Oct 14, 2008
    FRIDAY, Oct. 10 (HealthDay News) -- Blacks and the poor have worse outcomes when it comes to head and neck cancer, researchers say. In a new study, published in the Nov. 15 issue of Cancer, researchers examined the data on diagnosis, coexisting conditions, and procedures performed among 20,915 cases of head and neck cancer ... Specifically, the survival time among blacks was 21 months after being diagnosed with head and neck cancer, compared to 47 months among Hispanics and 40 months among... (MEDLINEplus)

    Introgen gets second notice from Nasdaq, says it will fight removal from exchange  Oct 7, 2008
    the Austin drug company working to bring a head and neck cancer treatment to the market, has received its second delisting notice in two months from the Nasdaq stock exchange ... In early September, Introgen was dealt a significant blow when the U.S. Food and Drug Administration declined to accept the company s application to market its head and neck cancer drug Advexin. (Austin Business Journal, TX)

    Eli Lilly bids $6.5 billion for ImClone  Oct 7, 2008
    " Lilly said it would incur a one-time charge to its earnings, but it is premature to say what that charge would be. The company expects the transaction to be accretive to earnings on a cash basis in 2012 and on a net basis in 2013. Cancer is one of the three main areas of research focus at Lilly, along with diabetes and neuroscience. But its main cancer drug, Gemzar, loses patent protection in 2012. Erbitux, which is approved to treat colon cancer and head and neck cancer, is ImClone's only... (Yahoo News -- Pharmaceutical Industry News)

    Bring On The Pak Choi: Consumers Interested In Trying More Asian Vegetables  Oct 6, 2008
    16, 2007) A new study among AARP members shows that just one additional serving of fruit and vegetables per day may lower your risk of head and neck cancer, but the data suggest that you may not want to stop. (May 18, 2007) It turns out Mom was right -- you should eat your broccoli. (Science Daily)

    Eli Lilly to buy ImClone for $6.5-billion  Oct 6, 2008
    Erbitux, which is approved to treat colon cancer and head and neck cancer, is ImClone's only marketed product, and generated $1. 3-billion in sales last year. (Globe and Mail -- Business)

    News from Cancer: Disparities in head and neck cancer patients  Oct 6, 2008
    A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer ... To investigate factors that impact survival from head and neck cancer, Dr. Leonidas Koniaris and colleagues at the University of Miami School of Medicine reviewed all head and neck cancer cases in Florida between 1998 and 2002 ... By mining information from the Florida Cancer Data System and the Florida Agency for Health Care Administration dataset,... (EurekAlert!)

    Anemia Drugs Linked To Stroke Study Deaths: FDA  Oct 3, 2008
    The committee also voted to recommend against the drugs' use in patients with breast or head and neck cancer. The new German study looked at the use of epoetin alfa as an aid to stroke recovery. (MEDLINEplus)

    Gliknik locks up licenses to develop cancer drugs  Sep 21, 2008
    The biotech firm, creating drugs for autoimmune diseases and cancer, reached an agreement with the , Baltimore and the for the drugs, which are now in clinical trials for head and neck cancer. We are encouraged by the novelty and clinical trial results to date of these drug candidates and pleased to become a clinical stage development company early in the progress of our company s growth, said Gliknik CEO Dr. David Block in a statement. (Baltimore Business Journal, MD)

    The fight of his life  Sep 20, 2008
    Until his illness, he was director of the Sydney Cancer Centre, director of the Sydney Head and Neck Cancer Institute, and professor of surgery at Sydney University since 2004. He was awarded an AM in 2005. (Sydney Morning Herald)

    Patient-Reported Health Scores May Predict Head, Neck Cancer Outcomes  Sep 19, 2008
    WEDNESDAY, Sept. 17 (HealthDay News) -- Self-reported physical health changes in the year after head and neck cancer patients are diagnosed may help predict their five-year survival, says a U.S. study ... 7) diagnosed with head and neck cancer between 1995 and 2005 ... The researchers concluded that it may prove useful to include a measure of general health and well-being to the care of patients with head and neck cancer, especially during the first year. (MEDLINEplus)

    Erbitux Extends Life for Head and Neck Cancer Patients  Sep 12, 2008
    The drug has been used successfully in metastatic colon cancer and now appears to also benefit patients with head and neck cancers. "This is the first treatment in 30 years to prolong survival in first-line recurrent and/or metastatic head and neck cancer," said lead researcher Dr. Jan B. Vermorken, of the Department of Oncology at Antwerp University Hospital, in Belgium ... For this phase III trial, Vermorken's group randomly assigned 442 patients with recurrent metastatic head and neck cancers... (MEDLINEplus)

    Now Back To Icahn  Sep 12, 2008
    The results of a study released Wednesday by ImClone showed that Erbitux, mainly used to treat colon cancer, would also be effective in the treatment of head and neck cancer. The late-stage human trial showed a median survival increase of 2. (Forbes -- Markets)

    ImClone mulls $6.1b buyout offer  Sep 11, 2008
    Yesterday, ImClone formally rejected that offer from Bristol-Myers, its partner in selling Erbitux, a treatment for colon and head and neck cancer. "In our view, this will force [Bristol-Myers's] hand to offer $70 with no due diligence conditions immediately," analyst Barbara Ryan wrote in a note to clients. (Boston Globe)

    ImClone's Erbitux Extends Head, Neck Cancer Survival in Study  Sep 11, 2008
    s Erbitux prolongs survival for patients with recurring head and neck cancer more than chemotherapy alone, a ``notable'' potential treatment improvement, according to a report in the ... About 40,000 people in the U.S. are diagnosed with head and neck cancer every year, and 40 percent have spreading disease. (Bloomberg)

    ImClone gets second takeover bid  Sep 11, 2008
    Erbitux, ImClone's main product, is approved to treat colon cancer and head and neck cancer. Any second bidder would have to deal closely with Bristol-Myers, which holds a 20 percent stake in ImClone. (International Herald Tribune -- Business)

    Recent Advances in Head and Neck Cancer  Sep 11, 2008
    Volume 359:1143-1154. Robert I. Haddad, M.D., and Dong M. Shin, M.D.. (New England Journal of Medicine)

    Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer  Sep 11, 2008
    Volume 359:1116-1127. Jan B. Vermorken, M.D., Ph. (New England Journal of Medicine)

    As head and neck cancer risks evolve, more treatment options emerge  Sep 11, 2008
    Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the New England Journal of Medicine ... At Winship, Shin is leading a head and neck cancer drug discovery program and conducting clinical trials aimed at preventing head and neck cancers from progressing or recurring ... He and his co-workers recently showed that a compound from green tea enhances the... (EurekAlert!)

    Introgen sell-off continues  Sep 5, 2008
    On Tuesday Austin-based Introgen announced the FDA had declined to accept its application to market Advexin, the head and neck cancer drug the company has spent more than a decade developing. That news prompted Introgen s (Nasdaq: INGN) stock to drop more than 35 percent on Tuesday to 57 cents a share. (Austin Business Journal, TX)

    FDA refuses Introgen application; stock in freefall  Sep 3, 2008
    Introgen (Nasdaq: INGN) says the FDA has notified the company that its application for its Advexin head and neck cancer treatment was not complete and would therefore not be filed at this time ... We believe in the potential of Advexin as a treatment option for head and neck cancer, an area of significant unmet need for today s cancer patient, says Introgen CEO David Nance ... We are encouraged by our clinical data and believe that the 40,000 Americans who are diagnosed with head and neck cancer... (Austin Business Journal, TX)

    ImClone: BMS offer for company seen reaching USD 67-70  Aug 29, 2008
    Alternatively, the person familiar said he believes that more mileage could be derived from Erbitux, which, in combination with radiation therapy, is indicated for the treatment of a certain type of locally or regionally advanced head and neck cancer. He said that going forward the drug in colorectal cancer has proven to double survival rates in third line and has proven results in non-small cell lung cancer, which he noted has a larger indication. (FT.com -- Markets)

    Cancer slows UConn coach Calhoun but doesn't stop him  Aug 26, 2008
    " The most recent battle began as soon as Calhoun realized he was dealing with something worse than an upper respiratory infection brought on by the end of another season. After telling his doctors the growth had increased in size, a biopsy was performed April 24. Jeffrey Spiro, co-director of the Multidisciplinary Head and Neck Cancer Team at the UConn Health Center, operated without Calhoun's condition becoming public knowledge, but it was obvious radiation treatments would change that. Spiro... (USA Today -- Sports)

    Cel-Sci lets Teva sell cancer drug  Aug 20, 2008
    The licensing agreement is initially restricted to the areas of head and neck cancer. Teva has the rights, subject to certain conditions, to extend the licensing agreement to include other cancers during the term of this agreement. (Washington Business Journal, DC)

    Adherex Reports Second Quarter 2008 Financial Results  Aug 13, 2008
    - In May, we completed a license agreement with the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL) for the exclusive use of data from a completed Phase III trial using sodium thiosulfate (STS) to prevent platinum-induced hearing loss in adults with head and neck cancer ... We also have plans to initiate a further Phase III trial with STS in adult head and neck cancer patients in the U.S. later this year. (CCNMatthews Press Releases)

    ImClone Calls Bristol Offer Too Low  Aug 5, 2008
    Erbitux is approved for colorectal and head and neck cancer in the United States, and Canada, while a recent approval for the drug in Japan and new lung cancer data are expected to drive sales. ImClone said it believed the pipeline business "may be extremely valuable and significantly increase stockholder value as a separate business.". (ABC News -- Wire)

    Wall Street slides on GDP, jobless data  Aug 1, 2008
    Bristol-Myers, which already owns about 17 percent of ImClone, is a U.S. partner for the colon and head and neck cancer drug Erbitux. ImClone surged $17. (San Diego Union-Tribune)

    Bristol-Myers offers $4.5 billion for ImClone  Aug 1, 2008
    New York-based Bristol-Myers already owns about 17 percent of ImClone and is a longtime U.S. partner on the colon and head and neck cancer drug Erbitux. In my view, and in the view of our board of directors, this transaction makes compelling business sense for both of our companies and is in the best interests of our respective shareholders and the cancer patients for whom our companies life saving medicines are so important, Bristol-Myers Chairman and Chief Executive James M. Cornelius... (MSNBC -- Business)

    Bristol offers to buy ImClone for $60 a share  Aug 1, 2008
    Bristol co-promotes Erbitux, which is approved for colorectal and head and neck cancer, in the United States, and Canada, while a recent approval for the drug in Japan and new lung cancer data are expected to drive sales. Germany's Merck KGaA () has rights to Erbitux in other countries. (Yahoo News -- Pharmaceutical Industry News)

    US stocks slide on GDP, jobless data  Aug 1, 2008
    Web search enhanced by. Friday August 1, 2008 MYT 12:17:42 PM. (The Star Online, Malaysia -- Business)

    U.S. regulator to tighten use of Amgen anemia drugs  Jul 31, 2008
    But the new labels will not advise against use of the drugs for all patients with breast cancer or head and neck cancer, something that had been recommended by an advisory panel to the FDA in March. One impact of the label changes could be to make it less likely that Medicare will loosen reimbursement policies for the drugs. (International Herald Tribune -- Money Report)

    Oncolytics Biotech Inc. Announces 2008 Second Quarter Results  Jul 30, 2008
    "Oncolytics experienced a strong second quarter with the reporting of durable clinical responses to REOLYSIN(R) combination therapy treatment in refractory head and neck cancer patients," said Dr. Brad Thompson, President and CEO of Oncolytics ... MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech Inc. as at and for the... (PR Newswire)

    Dr. Pou's trial changes laws and her life  Jul 30, 2008
    Today, she is busy as a head and neck cancer specialist and surgeon. She is on the faculty of LSU Health Sciences Center in New Orleans and treats her patients and the needy of the state, commuting to clinics set up in Baton Rouge. (WWLTV.com, LA)

    Teamwork Cuts Out Unnecessary Biopsies, Researchers Find  Jul 26, 2008
    ScienceDaily (July 25, 2008) Unnecessary biopsies could be a thing of the past for patients undergoing treatment for head and neck cancer ... Often used prior to and after cancer treatment, the highly sensitive PET-CT has improved the ability to detect and treat head and neck cancer ... Unnecessary biopsies are dangerous for head and neck cancer patients who have already undergone intensive radiation and chemotherapy. (Science Daily)

    Head And Neck Cancer: Quick Way To Determine If Cancer Has Spread  Jul 25, 2008
    ScienceDaily (July 24, 2008) For patients with head and neck cancer, accurately determining how advanced the cancer is and detecting secondary cancers usually means undergoing numerous tests - until now. New Saint Louis University research has found that the PET-CT scanner can be used as a stand-alone tool to detect secondary cancers, which occur in 5 to 10 percent of head and neck cancer patients ... The study findings, which were presented on July 22, at the 7th International Conference on... (Science Daily)

    US surgeons to honour RPA doctor  Jul 20, 2008
    The popular professor is in San Francisco, with his wife Gail, at the 7th International Conference on Head and Neck Cancer. A keynote lecture named in his honour will be delivered tomorrow. (Sydney Morning Herald -- Australia)

    Gene Variations In Diverse Patient Populations Determine Who Responds Best To An Antidepressant  Jul 17, 2008
    (May 19, 2008) Taking the antidepressant citalopram before beginning treatment for head and neck cancer may help prevent depression during therapy, according to results of a pilot. (Mar. (Science Daily)

    Adam Feuerstein  Jul 15, 2008
    But in his article Feuerstein says that "doesn't explain why survival for Advexin-treated patients overall was so low." He goes on to say: "Introgen says that 75 percent of head and neck cancer patients are 'Advexin favorable' so surely, that should translate into a survival benefit no matter how the patients are analyzed.". On June 30 Austin-based Introgen -- which has most of its staff and operations in Houston and only its executive team in Austin -- announced it had applied with the U.S.... (Austin Business Journal, TX)

    Amgen to Pay J&J $200 Million to Settle Antitrust Suit  Jul 13, 2008
    A panel of experts recommended in March that the U.S. Food and Drug Administration change the drugs' labels to say that they should not be given to patients with potentially curable cancers who are undergoing treatment, or to patients with advanced breast cancer or head and neck cancer. A decision by the FDA is expected any day. (ABC News -- Wire)

    Introgen cuts 29% of jobs as it moves to market cancer therapy  Jul 8, 2008
    Advexin p53 is designed to treat recurrent head and neck cancer. By harnessing the body's natural tumor-suppression mechanisms, the treatment fights cancer without some of the toxicities associated with conventional cancer treatments. (Austin Business Journal, TX)

    Introgen stock rises as company seeks FDA approval of cancer drug  Jul 1, 2008
    Advexin p53 is designed to treat recurrent head and neck cancer ... "With the use of p53 biomarkers, Advexin will provide more effective and less toxic treatment for head and neck cancer patients who have limited treatment options.". (Austin Business Journal, TX)

    GlaxoSmithKline, Exelixis to end 6-year collaboration  Jun 28, 2008
    The compound, now called GSK089, is in Phase II trials for papillary renal cell carcinoma, gastric cancer and head and neck cancer. GSK can pick an additional compound among six programs: XL184, which will start Phase III trials this summer for glioblastoma, medullary thyroid cancer and non-small cell lung cancer; XL820, in Phase II for gastrointestinal stromal tumor; XL281, in Phase I for patients with advanced solid tumors; XL228, in Phase I for chronic myelogenous leukemia, Philadelphia... (San Francisco Business Journal)

    Caphosol favorably impacts both the rate and severity of oral mucositis in cancer patients  Jun 28, 2008
    The most common malignancies among the participants were breast cancer (31 percent), head and neck cancer (31 percent) and colorectal cancer (11 percent) ... The use of Caphosol also had a favorable impact on the severity of OM: Mild OM (Grade 0/1) was found in more than 90 percent of chemotherapy patients and 40 percent of head and neck cancer patients ... Severe OM (Grade 3/4) was found in only 1-2 percent of chemotherapy patients and 18 percent of head and neck cancer patients (with only one... (EurekAlert!)

    Cancer center celebrates an anniversary  Jun 25, 2008
    "We have a whole generation of head and neck cancer patients who will never get surgery now because we have proved that combination therapy can be just as effective without the need for surgery," Foens said. "If those patients had to coordinate their treatments in Waterloo and Grundy Center or Mason City it would be very difficult for them to continue on with their daily activities. ... This kind of practice was revolutionary 20 years ago, but it is still meeting our patients' needs today.". (Waterloo-Cedar Falls Courier)

    YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL  Jun 20, 2008
    It is approved in several countries for treatment of various types of head and neck cancer. This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. (PR Newswire)

    An HIV-Positive Man with Cutaneous Merkel-Cell Carcinoma  Jun 19, 2008
    Dr. Gregory K. Robbins (Infectious Diseases): A 63-year-old man was referred to the clinic for head and neck cancer, a multidisciplinary unit of this hospital, for management of cutaneous Merkel-cell carcinoma. He had been well until 3 months earlier, when he noted a small, painless nodule on the superior, right-central aspect of his forehead. (New England Journal of Medicine)

    Combining Radiation And Surgery Significantly Improves Survival For Head And Neck Cancer Patients  Jun 15, 2008
    14, 2008) Adding radiation therapy to surgery significantly improves overall survival in patients diagnosed with node-positive head and neck cancer when compared to treating with surgery alone, according to a study in the June issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology ... Radiation therapy is commonly used after surgery to treat some head and neck cancers, but very few studies have... (Science Daily)

    Police chief battles cancer, speaks out against chew tobacco  Jun 5, 2008
    "I was still trying to recover from being cut head to toe when they sent me to chemo and radiation," said Hahn, 33, who was diagnosed with head and neck cancer in April 2007 ... Four days later Hahn was diagnosed with head and neck cancer and scheduled for emergency surgery at the Huntsman Cancer Institute at the University of Utah in Salt Lake City. (Casper Star-Tribune, WY)

    Anemia Drugs May Speed Tumor Growth in Some Cancer Patients  Jun 3, 2008
    They also voted to recommend against the drugs' use in patients with breast or head and neck cancer ... The results of the current study were based on analyses of tumor samples from 101 patients diagnosed with head and neck cancer who had participated in a previous phase III trial of erythropoietin. (MEDLINEplus)

    Acupuncture Eases Side Effects of Head, Neck Cancer Treatments  Jun 3, 2008
    SUNDAY, June 1 (HealthDay News) -- Two of the more common and unpleasant side effects of treatment for head and neck cancer patients may be relieved by the ancient Chinese practice of acupuncture ... Neck dissection, or removal of the lymph nodes and surrounding tissue, is common in treating head and neck cancers. (MEDLINEplus)

    Drugs show success in the treatment of several cancers  Jun 3, 2008
    Patients with locally advanced head and neck cancer may respond better to treatment when the drug cetuximab is added to standard chemotherapy, according to findings presented by University of Pittsburgh researchers yesterday in Chicago at the annual meeting of the American Society of Clinical Oncology. Out of 37 patients, 32 responded to initial therapy with that treatment regimen, and all patients had full or partial reduction of their tumors later after radiation treatment, said Dr. Ethan... (Pittsburgh Post Gazette)

    Study is seen as boost for ImClone  Jun 2, 2008
    It is also approved to treat head and neck cancer. But data presented here could change that. (Boston Globe)

    UPDATE:Colon Cancer Study Backs Gene's Role In Erbitux Benefit  Jun 2, 2008
    It is already approved to treat head and neck cancer, as well as colorectal cancer that has failed previous therapy. The response rate in the Erbitux arm was 59% in wild-type patients, compared to 43% in chemotherapy alone. (CNNMoney.com)

    Easing The Pain After Cancer Surgery  Jun 2, 2008
    Acupuncture eases pain in head and neck cancer surgery Posted: 02 June 2008 1510 hrs. Photos. (Channelnewsasia.com)

    Archives: Head and Neck Cancer

    Back to Health News

[ Terms Of Use | Privacy | About ]
©1998-2009 SurfWax, Inc.
All rights reserved. Patents pending.



Copyright SurfWax, Inc. 2009